US Biotechnology and Pharmaceuticals: Notable quotes from 2Q: Week1

Research evidence excerpt

US Biotechnology and Pharmaceuticals: Notable quotes from 2Q: Week1

Viewpoint |

31 Jul 2026 14:19:45 ET │ 16 pages

US Biotechnology and

Pharmaceuticals

Notable quotes from 2Q: Week 1

Geoff Meacham, Ph.D. AC

CITI'S TAKE +1-404-443-4701

geoffrey.meacham@citi.com

With 2Q earnings season underway, we highlight key quotes from the large-

cap biotech and pharma companies including our coverage and beyond. We Nishant Gandhi, Ph.D.

highlight commentary from leadership teams in Biopharma on the following +1-212-816-2513

topics: 1) AI initiatives, 2) capital allocation/ BD and 3) the GLP-1 landscape. nishant.gandhi@citi.com

We included quotes from each of these themes for the companies below.

Please click through to see quotes across Biopharma. Mary Kate Davis

+1-212-816-9602

mary.kate.davis@citi.comCommentary on AI

Jarwei Fang

GSK: “I'll tell you more about it, Steve, when we talk about early R&D and how we're

+1-212-816-5127

applying AI, not just to the idea of matching targets and patients and opportunity, jarwei.fang@citi.com

but designing molecules and ultimately making clinical trial execution more

effective. We've got 150 people in our AI group. These folks have PhDs in maths. We

don't unwrap other people's shrink-wrapped AI products.”

Bristol: “Over the past several years, BMS has embedded AI across its research and

enterprise operations, and demand for compute has grown alongside the scale and

maturity of our AI capabilities. In support of this expansion, we've recently

announced partnership agreements with both Anthropic and NVIDIA. Concretely,

this will help our scientists do three things, understand disease biology more

deeply, design and test candidate molecules faster, and make earlier, better

informed decisions about which programs to move forward.”